Mereo BioPharma Reports Third Quarter 2026 Financial Results
Lower operating expenses narrowed the quarterly loss, while potential alvelestat funding remains conditional on Sentynl exercising its option.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mereo BioPharma (MREO) reported a narrower third-quarter 2026 net loss while continuing regulatory discussions for its two core rare-disease programs. Net loss narrowed to $5.863 million from $7.024 million a year earlier, with lower research and administrative expenses. Cash was $26.1 million at September 30, down from $41.0 million at year-end 2025; Mereo expects funding to last into late-2027, excluding potential partnership payments.
Mereo and Ultragenyx are discussing whether setrusumab has a regulatory path forward in pediatric osteogenesis imperfecta. Mereo is also working with Sentynl to refine alvelestat’s Phase 3 design and prepare for a possible early-2027 start. Sentynl’s option exercise would bring $40 million in upfront and research payments, with up to $435 million in additional milestones and double-digit tiered U.S. royalties. The option remains unexercised.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter net loss narrowed to $5.863 million from $7.024 million in 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Existing cash is expected to fund operations into late-2027, excluding potential business-development payments.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Sentynl option exercise would provide $40 million in upfront and research payments to fund alvelestat’s Phase 3 study. 89% of market cap
- Minor pointThird-quarter revenue rose to $800,000 from zero a year earlier.
- Minor pointThird-quarter research and development expenses fell to $2.090 million from $4.270 million a year earlier.
10 minor points
- Minor pointThird-quarter administrative expenses fell to $4.928 million from $6.045 million a year earlier.
- Minor pointNine-month net loss narrowed to $19.587 million from $34.527 million in 2025.
- Minor pointNine-month revenue increased to $800,000 from $500,000 in 2025.
- Minor pointNine-month research and development expenses declined to $8.645 million from $13.573 million in 2025.
- Minor pointNine-month administrative expenses declined to $14.169 million from $18.811 million in 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Alvelestat agreement offers eligibility for up to $435 million in milestones and double-digit tiered U.S. royalties.
- Minor point. Forward-looking: it has not happened yet and may not happen.Alvelestat preparations target readiness for an early-2027 Phase 3 start; Mereo expects an update before year-end.
- Minor pointSetrusumab subgroup analyses showed benefit, in Mereo’s assessment, among patients with at least 3 fractures in the prior 2 years.
- Minor pointVantictumab legacy cancer-study data showed increased bone-resorbing cell activity at low doses without inhibiting bone-forming cell activity.
- Minor point. Forward-looking: it has not happened yet and may not happen.Vantictumab partner āshibio intends to initiate ADO2 clinical trials in the first half of 2028.
Negative
- Moderate pointCash declined to $26.1 million at September 30, 2026 from $41.0 million at December 31, 2025.
- Moderate pointSetrusumab’s potential regulatory path remains unresolved; discussions concern data needed to support a filing.
- Moderate pointAlvelestat’s option remains conditional on Sentynl’s exercise; Phase 3 design is still under FDA discussion.
- Minor pointSetrusumab spending reductions included delays to manufacturing investment and ongoing activities, including European medical affairs.
- Minor pointThird-quarter interest income fell to $241,000 from $504,000 a year earlier.
5 minor points
- Minor pointThird-quarter foreign currency transaction gain fell to $29,000 from $1.873 million a year earlier.
- Minor pointThird-quarter research tax-credit benefit fell to $97,000 from $446,000 a year earlier.
- Minor pointNine-month interest income declined to $846,000 from $1.752 million in 2025.
- Minor pointNine-month research tax-credit benefit declined to $311,000 from $1.377 million in 2025.
- Minor pointIssued ordinary shares increased to 798,454,864 at September 30, 2026, from 795,658,504 at year-end 2025.
Details
Market move: MREO +5.16% vs previous close. 3Q26 earnings report
On Nov 9, the day this news came out, the latest delayed price for MREO is 5.16% above the previous close. Our momentum scanner has recorded 10 alerts for this stock so far that day. The latest delayed price is $0.30. Relative volume is above average at 1.7x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- R&D expenses
- $2.1 million, down from $4.3 million
- Third quarter 2026 vs. third quarter 2025
- G&A expenses
- $4.9 million, down from $6.0 million
- Third quarter 2026 vs. third quarter 2025
- Net loss
- $5.9 million, compared with $7.0 million
- Third quarter 2026 vs. third quarter 2025
- Cash and cash equivalents
- $26.1 million
- As of September 30, 2026
- Cash runway
- Into late-2027
- Based on current operational plans; excludes potential business-development payments
- Upfront and R&D payments
- $40 million
- Potential payments if Sentynl exercises its alvelestat option
- Regulatory and commercial milestones
- Up to $435 million
- Potential alvelestat agreement payments
Previous Earnings Reports
-
Q2 report documented Sentynl agreement terms and late-2027 runway alongside reduced expenses.
-
Same-quarter results establish prior R&D, G&A and cash levels for comparison with Q3 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
annual fracture rate medical
post-hoc analyses technical
bone mineral density medical
phase 3 medical
osteogenesis imperfecta medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI)
Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine Phase 3 trial design for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)
Cash and cash equivalents of
LONDON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the third quarter ended September 30, 2026, and provided an update on its late-stage programs.
“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve,” said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma. “In collaboration with our partner Ultragenyx, we are continuing to work closely with the regulators, to determine the necessary data to support a regulatory submission for setrusumab in OI and if there is a potential path forward. We believe that the data from post-hoc fracture analyses presented at the recent American Society for Bone and Mineral Research (ASBMR) Annual Meeting further support setrusumab’s potential to provide meaningful benefit, particularly in pediatric, higher fracturing patients. We are also advancing our regulatory interactions on alvelestat for AATD-LD alongside Sentynl Therapeutics to streamline the Phase 3 design and are working to be in a position to initiate the Phase 3 study in early 2027. We continue to expect that our current cash position, which totaled
Recent Developments and Anticipated Milestones
Setrusumab (UX143) for osteogenesis imperfecta (OI)
- Following the results of the Orbit and Cosmic Phase 3 studies of setrusumab in OI, reported in December 2025, Mereo and its partner, Ultragenyx Pharmaceutical, Inc. (Ultragenyx), have engaged with regulatory agencies to determine a potential path forward for setrusumab in pediatric OI patients. These interactions have focused on understanding the necessary data to support a regulatory filing and if there is a potential path forward.
- Data from pre- and post-hoc analyses from both the Orbit and Cosmic studies were presented at the 2026 ASBMR Annual Meeting held in October. These data included baseline characteristics, as well as annual fracture rate (AFR) analyses in certain patient subgroups. These pre- and post-hoc analyses on total fractures in patients enrolled with at least 3 fractures in the prior 2 years showed a meaningful benefit on fractures, bone mineral density and other endpoints in the two Phase 3 studies.
Alvelestat (MPH-966) for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)
- In August, Mereo announced an option and license agreement with Sentynl Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus Lifesciences Limited, which granted Sentynl the right to acquire a license for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
- Should Sentynl exercise its option during the short option period, Mereo would receive
$40 million in upfront and R&D payments which would provide funding for the Phase 3 study. Mereo would also be eligible to receive up to$435 million in regulatory and commercial milestones, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and all regulatory interactions until study completion. - Since signing the option and license agreement, the companies have been collaborating to streamline the design of the planned Phase 3 study. In parallel, Mereo has been working to be in a position to initiate the Phase 3 study in early 2027.
- Based on ongoing FDA interactions, Mereo expects to provide an update before the end of the year.
Vantictumab (OMP18R5) for autosomal dominant osteopetrosis type 2 (ADO2)
- āshibio, Inc. (āshibio), Mereo’s development and commercial partner for vantictumab, reported clinical biomarker data from a legacy study of vantictumab in patients with cancer at the 2026 ASBMR Annual Meeting.
- These data showed that low doses of vantictumab (0.5-5mg/kg) administered once weekly or once every two or three weeks, increased osteoclast activity without inhibiting osteoblast activity at these low doses.
- Results were consistent with the findings from an ADO2 mouse study presented by āshibio at the 2025 ASBMR Annual Meeting showing that low doses of vantictumab increased osteoclast activity and rescued the osteopetrotic bone phenotype in this animal model.
- āshibio is continuing to advance vantictumab toward clinical trials in patients with ADO2 and intends to initiate trials in the first half of 2028.
Third Quarter 2026 Financial Results
Total research and development (“R&D”) expenses decreased by
General and administrative (“G&A”) expenses decreased by
Net loss for the third quarter of 2026 was
As of September 30, 2026, the Company had cash and cash equivalents of
Total ordinary shares issued as of September 30, 2026 were 798,454,864. Total ADS equivalents as of September 30, 2026 were 159,690,972, with each ADS representing five ordinary shares of the Company.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company seeks to combine partnerships that provide validation for its programs and non-dilutive capital to fund late-stage clinical development, with the upside of retaining commercial rights in key strategic territories, including Europe. The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights to commercialize alvelestat for AATD-LD, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with āshibio, Inc., for vantictumab in autosomal dominant osteopetrosis type 2 (ADO2). āshibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.
Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company’s reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company’s dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company’s dependence on its key executives; and the Company’s ability to maintain compliance with Nasdaq continued listing requirements.
You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook,” “will,” “continue” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company’s current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.
| Mereo BioPharma Contacts: | |
| Mereo | +44 (0)333 023 7300 |
| Denise Scots-Knight, Chief Executive Officer | |
| Christine Fox, Chief Financial Officer | |
| Burns McClellan (Investor Relations Adviser to Mereo) | +01 646 930 4406 |
| Lee Roth | |
| Investors | investors@mereobiopharma.com |
| MEREO BIOPHARMA GROUP PLC CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) | |||||||
| September 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 26,097 | $ | 40,992 | |||
| Prepaid expenses and other current assets | 2,269 | 2,531 | |||||
| Research and development incentives receivables | 306 | 1,497 | |||||
| Total current assets | 28,672 | 45,020 | |||||
| Property and equipment, net | 24 | 137 | |||||
| Operating lease right-of-use assets, net | 758 | 244 | |||||
| Intangible assets, net | 129 | 516 | |||||
| Total assets | $ | 29,583 | $ | 45,917 | |||
| Liabilities | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,004 | $ | 1,333 | |||
| Accrued expenses | 3,017 | 2,026 | |||||
| Operating lease liabilities – current | 577 | 202 | |||||
| Warrant liabilities – current | 8 | — | |||||
| Other current liabilities | 888 | 741 | |||||
| Total current liabilities | 5,494 | 4,302 | |||||
| Warrant liabilities – non-current | 8 | 38 | |||||
| Other non-current liabilities | 370 | 661 | |||||
| Total liabilities | $ | 5,872 | $ | 5,001 | |||
| Shareholders’ Equity | |||||||
| Ordinary shares, par value | $ | 3,146 | $ | 3,135 | |||
| Additional paid-in capital | 553,243 | 549,622 | |||||
| Accumulated deficit | (520,406 | ) | (501,018 | ) | |||
| Accumulated other comprehensive loss | (12,272 | ) | (10,823 | ) | |||
| Total shareholders’ equity | $ | 23,711 | $ | 40,916 | |||
| Total liabilities and shareholders’ equity | $ | 29,583 | $ | 45,917 | |||
| MEREO BIOPHARMA GROUP PLC CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | $ | 800 | $ | — | $ | 800 | $ | 500 | |||||||
| Operating expenses | |||||||||||||||
| Cost of revenue | — | — | — | (133 | ) | ||||||||||
| Research and development | (2,090 | ) | (4,270 | ) | (8,645 | ) | (13,573 | ) | |||||||
| General and administrative | (4,928 | ) | (6,045 | ) | (14,169 | ) | (18,811 | ) | |||||||
| Other income | — | 300 | — | 300 | |||||||||||
| Loss from operations | (6,218 | ) | (10,015 | ) | (22,014 | ) | (31,717 | ) | |||||||
| Other income/(expenses) | |||||||||||||||
| Interest income | 241 | 504 | 846 | 1,752 | |||||||||||
| Interest expense | (10 | ) | (28 | ) | (47 | ) | (232 | ) | |||||||
| Changes in the fair value of warrants | (2 | ) | 196 | 21 | 511 | ||||||||||
| Foreign currency transaction gain/(loss), net | 29 | 1,873 | 1,296 | (6,218 | ) | ||||||||||
| Benefit from research and development tax credit | 97 | 446 | 311 | 1,377 | |||||||||||
| Net loss before income tax | (5,863 | ) | (7,024 | ) | (19,587 | ) | (34,527 | ) | |||||||
| Income tax benefit | — | — | — | — | |||||||||||
| Net loss | $ | (5,863 | ) | $ | (7,024 | ) | $ | (19,587 | ) | $ | (34,527 | ) | |||
| Loss per share – basic and diluted | $ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.04 | ) | |||
| Weighted average shares outstanding – basic and diluted | 804,533,827 | 799,947,013 | 803,310,695 | 796,018,903 | |||||||||||
| Net loss | $ | (5,863 | ) | $ | (7,024 | ) | $ | (19,587 | ) | $ | (34,527 | ) | |||
| Other comprehensive income/(loss) – Foreign currency translation adjustments, net of tax | 13 | (2,267 | ) | (1,449 | ) | 7,939 | |||||||||
| Total comprehensive loss | $ | (5,850 | ) | $ | (9,291 | ) | $ | (21,036 | ) | $ | (26,588 | ) | |||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Mereo BioPharma’s third-quarter 2026 financial results?
Mereo reported a $5.863 million net loss, compared with $7.024 million in the third quarter of 2025. Revenue was $800,000 versus zero a year earlier. Research and development expenses fell to $2.090 million from $4.270 million, while administrative expenses declined to $4.928 million from $6.045 million.
How long does Mreo BioPharma expect its September 2026 cash to last?
Mereo expects its $26.1 million cash balance at September 30, 2026, to fund committed clinical trials, operating expenses and capital expenditure requirements into late-2027. That outlook excludes potential future business-development payments, including payments associated with Sentynl exercising its alvelestat option.
What rights would Sentynl receive under Mereo’s alvelestat agreement?
Sentynl has an option to license U.S. commercial rights and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease. Mereo retains commercial rights outside the United States and will lead the global Phase 3 study and regulatory interactions until study completion.
What evidence supports Mereo’s planned vantictumab trials for ADO2?
Legacy cancer-study biomarker data showed that low-dose vantictumab increased bone-resorbing cell activity without inhibiting bone-forming cell activity. Doses of 0.5–5mg/kg were administered weekly or every two or three weeks. These findings were consistent with an earlier mouse study; they were not clinical results in patients with autosomal dominant osteopetrosis type 2.